Quarterly ResultMay 6, 2026, 04:19 PM
Vir Bio Q1 Net Loss $125.7M; Astellas VIR-5500 Deal Closed
AI Summary
Vir Biotechnology reported its first quarter 2026 financial results, with a net loss of $125.7 million and a strong cash position of $809.3 million. The company highlighted significant corporate momentum, including the closing of its global strategic collaboration with Astellas for VIR-5500 in prostate cancer, with the first patient dosed in Phase 1 expansion cohorts. Additionally, Vir Bio will present complete Week 96 Phase 2 SOLSTICE data for its chronic hepatitis delta combination regimen at the upcoming EASL Congress, and expects its cash runway to extend into the second half of 2028.
Key Highlights
- Cash, cash equivalents, and investments totaled $809.3 million as of March 31, 2026.
- Net loss for Q1 2026 was $125.7 million, or $0.85 per share.
- R&D expenses decreased to $108.9 million in Q1 2026 from $118.6 million in Q1 2025.
- SG&A expenses were $23.3 million in Q1 2026, down from $23.9 million in Q1 2025.
- Global strategic collaboration with Astellas for VIR-5500 closed; first patient dosed in Phase 1 expansion.
- Company completed a public offering of common stock, generating $172.5 million in gross proceeds.
- Will present complete Week 96 Phase 2 SOLSTICE data for chronic hepatitis delta at EASL Congress.
- Expects cash, cash equivalents, and investments to fund operations into the second half of 2028.